|
FY2024
12 months to Dec 31, 2024
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
FY2020
12 months to Dec 31, 2020
|
FY2019
12 months to Dec 31, 2019
|
|
|---|---|---|---|---|---|
| Revenue | |||||
| Provider | |||||
| Payer and Life Science | |||||
| Total revenue | |||||
| Cost of revenue | |||||
| Provider | |||||
| Payer and Life Science | |||||
| Cost of revenue | |||||
| Gross profit | |||||
| Selling, general and administrative expenses | |||||
| Research and development | |||||
| Asset impairment charges | |||||
| Amortization of intangible and acquisition-related assets | |||||
| Impairment of goodwill and other assets | |||||
| Amortization of intangibles | |||||
| Income (loss) from operations | |||||
| Interest expense | |||||
| Interest income | |||||
| Insurance recoveries | |||||
| Other income (expense), net | |||||
| Gain (loss) on sale of businesses, net | |||||
| Impairment of long-term investments | |||||
| Income (loss) from continuing operations before income taxes | |||||
| Income tax benefit (provision) | |||||
| Income (loss) from consolidated continuing operations, net of tax | |||||
| Equity in net loss of unconsolidated subsidiaries, net of tax | |||||
| Income (loss) from continuing operations, net of tax | |||||
| Loss from discontinued operations | |||||
| Loss on sale of discontinued operations | |||||
| Income tax effect on discontinued operations | |||||
| Loss from discontinued operations, net of tax | |||||
| Net income (loss) | |||||
| Net loss attributable to noncontrolling interests | |||||
| Net income (loss) attributable to Veradigm Inc. | |||||
| Basic | |||||
| Continuing operations | |||||
| Discontinued operations | |||||
| Net basic earnings (loss) per common share | |||||
| Diluted | |||||
| Continuing operations | |||||
| Discontinued operations | |||||
| Net income (loss) per share - Diluted | |||||
Loading...